End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5 TWD | -9.91% | -.--% | -71.75% |
04-30 | GeneTouch Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | GeneTouch Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Capitalization 1 | 231.6 | 178.3 | 228.3 | 353.8 |
Enterprise Value (EV) 1 | 241.8 | 275.6 | 337.6 | 396.2 |
P/E ratio | 42.5 x | 14.1 x | 353 x | -4.71 x |
Yield | - | - | - | - |
Capitalization / Revenue | 1.21 x | 0.61 x | 0.81 x | 1.85 x |
EV / Revenue | 1.26 x | 0.94 x | 1.19 x | 2.08 x |
EV / EBITDA | -24 x | 18.1 x | 56.7 x | -6.62 x |
EV / FCF | -6.28 x | -3.06 x | -9.54 x | 23.3 x |
FCF Yield | -15.9% | -32.6% | -10.5% | 4.3% |
Price to Book | 2.81 x | 1.87 x | 1.64 x | 2.41 x |
Nbr of stocks (in thousands) | 12,688 | 12,688 | 16,188 | 19,988 |
Reference price 2 | 18.25 | 14.05 | 14.10 | 17.70 |
Announcement Date | 21-04-23 | 22-04-20 | 23-04-17 | 24-04-30 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 174.7 | 119.3 | 192 | 294 | 282.6 | 190.9 |
EBITDA 1 | 5.495 | -29.1 | -10.06 | 15.23 | 5.954 | -59.82 |
EBIT 1 | 1.806 | -31.09 | -12.57 | 12.68 | 1.738 | -65.87 |
Operating Margin | 1.03% | -26.06% | -6.55% | 4.32% | 0.62% | -34.5% |
Earnings before Tax (EBT) 1 | 2.834 | -31.93 | 3.423 | 12.69 | 0.59 | -68.16 |
Net income 1 | 2.834 | -31.9 | 3.423 | 12.69 | 0.59 | -68.16 |
Net margin | 1.62% | -26.74% | 1.78% | 4.32% | 0.21% | -35.7% |
EPS 2 | 0.4700 | -5.860 | 0.4292 | 1.000 | 0.0400 | -3.761 |
Free Cash Flow 1 | -13.1 | 12.23 | -38.51 | -89.95 | -35.4 | 17.02 |
FCF margin | -7.5% | 10.25% | -20.06% | -30.6% | -12.53% | 8.92% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 20-10-16 | 21-04-23 | 21-04-23 | 22-04-20 | 23-04-17 | 24-04-30 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 14.8 | 27.7 | 10.2 | 97.3 | 109 | 42.4 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.694 x | -0.9508 x | -1.016 x | 6.389 x | 18.37 x | -0.7087 x |
Free Cash Flow 1 | -13.1 | 12.2 | -38.5 | -89.9 | -35.4 | 17 |
ROE (net income / shareholders' equity) | 4.31% | -115% | 6.86% | 14.3% | 0.5% | -47.7% |
ROA (Net income/ Total Assets) | 0.85% | -17.6% | -4.51% | 2.67% | 0.31% | -11.2% |
Assets 1 | 331.7 | 181.6 | -75.9 | 476.3 | 192.4 | 606.6 |
Book Value Per Share 2 | 7.080 | 3.150 | 6.500 | 7.500 | 8.590 | 7.350 |
Cash Flow per Share 2 | 4.690 | 6.580 | 5.550 | 6.250 | 4.460 | 3.900 |
Capex | - | 0.23 | 2.99 | 0.28 | 13.9 | 5.77 |
Capex / Sales | - | 0.19% | 1.56% | 0.09% | 4.9% | 3.02% |
Announcement Date | 20-10-16 | 21-04-23 | 21-04-23 | 22-04-20 | 23-04-17 | 24-04-30 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-71.75% | 3.08M | |
+26.96% | 33.28B | |
+0.93% | 10.9B | |
+26.65% | 8.88B | |
-2.48% | 4.2B | |
-0.70% | 4.2B | |
-9.34% | 4.16B | |
-17.70% | 3.77B | |
+3.11% | 3.36B | |
-32.68% | 2.46B |
- Stock Market
- Equities
- 6813 Stock
- Financials GeneTouch Corporation